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ABSTRACT 
Mantle cell lymphoma (MCL) is usually CD23-negative, a feature helpful in distinguishing MCL 
from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, a 
subset of MCL cases can be CD23+.  Limited data are available regarding the clinicopathologic 
features and prognosis of patients with CD23+ MCL. In this study, we reviewed 798 cases of 
MCL and identified 103 (13%) that were CD23+ by flow cytometry, all of which were positive 
for cyclin D1 and/or associated with CCND1/IGH. In all cases of CD23+ MCL, CD23 
expression was dim partial or dim, unlike moderate to bright CD23 expression observed in 
CLL/SLL. The clinicopathologic features and outcome of patients with CD23+ MCL were 
compared with 240 patients with typical MCL negative for CD23. Patients with CD23+ MCL 
more often had an elevated leukocyte count (33% vs 18%, p=0.009), bone marrow involvement 
(89% vs 78%, p=0.02), stage 4 disease (87% vs 77%, p=0.03) and a leukemic presentation (42% 
vs 11%, p=0.0001). CD23+ MCL was also more often positive for CD200 (17% vs. 4.6%, 
p=0.0005) and less commonly positive for SOX11 (55% vs. 74%, p=0.027).  All other 
clinicopathologic features were similar.  With similar treatment regimens and observation times, 
patients with CD23+ MCL had a significant better overall survival (p=0.02) and progression-free 
survival (p=0.029). In conclusion, CD23 expression was observed in 13% of MCL cases and is 
associated with a better prognosis in patients with MCL. CD23 is associated with leukocytosis, a 
leukemic presentation, bone marrow involvement, CD200 expression, and a lower frequency of 
SOX11 positivity. 
Key Words: CD23, mantle cell lymphoma, CD200, prognosis 
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1. INTRODUCTION 
Mantle cell lymphoma (MCL) is a distinctive type of B-cell lymphoma that represents 4-9% of 
all cases of non-Hodgkin lymphoma depending on geographic region.[1] The genetic hallmark of 
MCL is t(11;14)(q13;q32) which juxtaposes CCND1 on chromosome 11q13 with IGH on 
chromosome 14q32, resulting in overexpression of cyclin D1. Over-expression of cyclin D1 
leads to cell cycle dysregulation and uncontrolled lymphoma cell growth. Patients with MCL 
have a poorer prognosis than patients with other types of small B-cell lymphoma; the median 
overall survival of MCL patients reported in the literature is 3 – 5 years. The treatment regimens 
for MCL are therefore more intensive, unlike the therapies for other small B-cell lymphomas.[2] 
Nevertheless, as currently defined, MCL is heterogeneous with variable morphologic, 
immunophenotypic, cytogenetic, and molecular features as well as outcomes.[3-6]  Recently, 
leukemic non-nodal forms of MCL that are clinically indolent have been reported in a small 
subset of patients [2, 4-9]. Patients with leukemic non-nodal MCL present with peripheral blood, 
bone marrow, and/or splenic involvement, but lack significant lymphadenopathy, the latter 
defined as lymph nodes <1-2cm by imaging studies.[10] 
Mantle cell lymphoma has a distinctive immunophenotype, typically positive for pan B-cell 
markers, CD5 and cyclin D1, but negative for CD10, CD23, and CD200. Although most cases 
show this immunophenotype, some MCL cases have atypical immunophenotypic features, such 
as expression of CD10, CD23, or rarely CD200 or lack of expression of CD5. Earlier studies in 
the literature have shown that CD23 expression is the most common variant immunophenotypic 
finding in MCL.  
CD23 is a transmembrane molecule that functions as a low-affinity IgE Fc receptor. CD23 is 
present in a wide variety of cell types including B cells, activated T cells, macrophages, 
eosinophils, platelets, follicular dendritic cells, and natural killer cells.[11] Schuurman et al first 
described CD23 as a marker for distinguishing MCL from CLL using frozen section 
immunohistochemical analysis.[12] Subsequent studies performed using blood smears, fresh or 
frozen or paraffin-embedded tissue specimens, and immunohistochemical analysis and flow 
cytometry immunophenotypic analysis also showed a significant difference in CD23 expression 
between MCL and CLL/SLL.[13-20] It was therefore generally accepted that CD23 is expressed 
in CLL/SLL, but is usually negative in MCL.[16] However, subsequent studies, mainly using 
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flow cytometry methods with improved sensitivity, have shown that a small subset of MCL cases 
also express CD23.[16, 21, 22] Although a few studies on CD23 expression in MCL have been 
reported, most studies have reported a small number of cases and data regarding the 
clinicopathologic features and prognosis of patients with CD23+ MCL are limited.    
In this retrospective study, we review a large series of CD23+ MCL cases and we assess the 
clinicopathologic features, immunophenotype, and prognosis of patients with CD23+ MCL. 
 
 
2. MATERIALS AND METHODS 
2.1 Case Selection 
We searched the database of the Department of Hematopathology at The University of Texas 
MD Anderson Cancer Center from 2008 to 2016 for cases of MCL that were positive for CD23. 
The diagnosis of MCL was based on morphologic and immunophenotypic criteria as specified in 
the World Health Organization (WHO) classification. Specifically all cases had cyclin D1 
expression by immunohistochemistry (IHC) and/or evidence of t(11;14)(q13;q32)/CCND1-IGH 
or variant translocation confirmed by fluorescence in situ hybridization (FISH) or conventional 
karyotype analysis. Clinical information was obtained by review of the medical records. The 
clinicopathologic and immunophenotypic, features, overall survival (OS), and progression-free 
survival (PFS) of patients with CD23+ MCL were compared with 240 randomly chosen, well-
characterized CD23-negative MCL cases, which were from the same time period with a similar 
distribution over the years as the CD23+ MCL group. This study included 17 cases that were 
reported previously in an independently performed study of CD200 expression in MCL.
19
 The 
study was approved by the institutional review board. 
 
2.2 Immunophenotypic Studies 
All cases were analyzed with FACSCalibur
TM
 cytometers (BD Biosciences, San Jose, CA) 
before 2009, and with Canto II 8-color instruments (BD Biosciences) after 2009 as has been 
described.[23, 24] Briefly, the panel of antibodies used was variable over the years, but usually 
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included CD3, CD5, CD10, FMC7, CD19, CD20, CD23, CD38, CD43, CD200 and surface 
immunoglobulin kappa and lambda light chains. All antibodies were obtained from Becton-
Dickinson Biosciences.  Lymphocytes were gated for analysis using CD45 expression and side 
scatter. CD23 expression were assessed on CD5+/CD19+ aberrant B cell population, with T cells 
as internal negative control and also fluorescence minus one as control. CD23 expression was 
defined as positive when at least 20% of aberrant B cells had expression, an arbitrary cutoff used 
to define positive expression in most of the biomarker studies by flow cytometry analysis. 
 
Immunohistochemical studies were performed using formalin-fixed, paraffin-embedded tissue 
sections, either at the time of diagnosis or retrospectively for this study. After deparaffinization 
and dehydration of sections in graded alcohols and xylene, endogenous peroxidase was blocked 
with hydrogen peroxide. Heat-induced epitope retrieval was performed using citrate buffer, pH 
6.0. The panel of monoclonal antibodies used was variable over time, but included reagents 
specific for CD3 polyclonal, DAKO, Carpinteria, CA, USA), CD5 (Novocastra, Newcastle-on-
Tyne, UK), CD10 (DAKO), CD20 (DAKO), CD23 (Zymed, South San Francisco, CA, USA), 
BCL2 (clone 124, DAKO), BCL6 (DAKO), Ki-67 (DAKO); SOX-11(Cell Marque, Rocklin, 
California, USA) and cyclin D1 (clone AM29, NeoMarkers, Fremont, CA). The cutoff for 
positive SOX11 expression was defined as expression in ≥10% of cells as reported 
previously.[25] 
 
2.3 Cytogenetic Studies 
Conventional G-band karyotype analysis was performed on 24 cases using cell suspensions of 
lymph node, extranodal tissue specimens, or bone marrow aspirate specimens according to 
standard laboratory procedures as have been described.[26] The karyotypes were reported 
according to the 2016 International System for Human Cytogenetic Nomenclature.[27] 
 
Fluorescence in situ hybridization (FISH) analysis was performed on 63 cases using a dual color 
and dual fusion probe set for CCND1/IGH (Abbott Molecular, Downers Grove, IL, USA). For 
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bone marrow aspirate specimens, FISH was performed by using a freshly dropped slide from a 
harvested bone marrow aspirate specimen or a G-banded slide for metaphase mapping according 
to the manufacturer’s instructions. For formalin-fixed, paraffin-embedded tissue samples, FISH 
was performed on 4-mm tissue sections and fixed onto slides as per the manufacturer’s 
protocols. At least 200 interphase nuclei were analyzed and the sample was considered positive 
for CCND1 rearrangement if more than 2% of nuclei showed positive fusion signals. 
 
2.4 Statistical Analysis 
The Fisher exact test was utilized to analyze differences between the CD23+ and CD23-negative 
groups. OS was calculated from the date of diagnosis to the date of death or last follow-up. PFS 
was calculated from the date of diagnosis to the date of progression/relapse or, if no 
progression/relapse, the date of death or last follow-up. Patient survival was analyzed using the 
Kaplan–Meier method and compared using the log-rank test. Univariate and multivariate Cox 
proportional hazards model analyses for OS and PFS were performed by SPSS 22.0 software). A 
P-value of less than 0.05 was considered statistically significant. 
 
 
3. RESULTS 
3.1 Clinical Characteristics 
From a total of 798 MCL cases evaluated by flow cytometry immunophenotypic analysis, 103 
(13%) were CD23+ and formed the study group. There were 81 men and 22 women with a 
median age of 65 years (range, 44 to 88 years) at the time of diagnosis of MCL (Table I). Sixty-
seven (65%) patients were older than 60 years old and there was a male predominance. Of 89 
patients with a complete blood count (CBC) available at diagnosis, 29 (33%) had a leucocyte 
count above the normal upper limit (10 x 10 
9
/mm
3
).  Twenty-three of 88 (26%) patients had an 
elevated serum lactate dehydrogenase (LDH) level, 90 (87%) patients had an advanced Ann 
Arbor stage (stage IV), and 15 (18%) patients had a high MCL international prognostic index 
(MIPI) score [28, 29]. Bone marrow (BM) involvement was detected in 90 of 101 (89%) patients 
and 43 (42%) patients had a leukemic non-nodal presentation.  
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CD23+ MCL patients were younger than CD23-negative MCL patients (median age 63 vs. 67 
years, p=0.02) (Table I). Patients with CD23+ MCL also more commonly had a leukemic non-
nodal presentation (42% vs 11%, P=0.0001) and elevated leukocyte count (P=0.009), largely due 
to significantly increased circulating lymphoma cells (P=0.03). Stage 4 disease with bone 
marrow involvement was more common in the CD23+ MCL patients, mostly attributable to the 
leukemic non-nodal presentation. The MIPI score and serum LDH level were similar between 
the two groups.  
 
Among the 103 cases of CD23+ MCL, 53 cases had been assessed for SOX11 expression by 
immunohistochemistry and 29 cases were positive. The clinical features were further compared 
between patients with CD23+/SOX11+ MCL and those with CD23+/SOX11-negative MCL. 
Most features were similar between these subgroups (p>0.05) except that more patients were 
under observation in the CD23+/SOX11-negative group (Table II; 36% in SOX11-negative vs 
11% in SOX11+ group). 
 
Among the 103 cases of CD23+ MCL, 43 cases were leukemic non-nodal (LNN) form and 60 
were non-LNN. The clinical features were further compared between these two sub-groups.  
Patients with LNN disease had a significantly higher white blood cell count; more frequently had 
a high MIPI; more commonly had bone marrow involvement and therefore stage 4 disease; more 
frequent CD200 expression, and less frequently had a high Ki67 proliferation rate (Table III, 
p<0.05).  Other features were similar between these groups.   
 
3.2 Morphologic and Immunophenotypic findings 
83 of 103 (81%) CD23+ MCL cases had classical morphology (Figure 1) and the remaining 20 
(19%) cases had blastoid or pleomorphic morphology (Table I). All 96 cases tested for cyclin D1 
by immunohistochemistry (Figure 1) were positive. The 7 cases not tested for cyclin D1 were 
positive for CCND1 rearrangement by FISH. All MCL cases showed moderate to bright CD20 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
8 
 
expression (Figure 1) and at least moderate light chain expression, except one case with dim 
kappa light chain. 97 (94%) of CD23+ MCL cases were positive for CD5 and 2 (1.9%) cases 
were positive for CD10. SOX11 was assessed by immunohistochemistry in 53 cases and was 
positive in 29 (55%). 
 
CD23 expression was detected by flow cytometry in all cases; 69 (67%) cases exhibited partial 
dim CD23 expression and 34 (33%) cases had dim or occasionally dim to moderate expression. 
No cases strongly expressed CD23. (Figure 1). Fifteen CD23+ MCL cases were also assessed for 
CD23 by immunohistochemistry.  Six of 13 MCL cases with dim partial CD23 expression were 
positive by immunohistochemistry and 7 cases were negative.  Two cases of MCL with uniform 
dim CD23 expression were also positive by immunohistochemistry.   
 
All MCL cases were assessed for CD200 expression by flow cytometry which was positive in 17 
(16.5%) cases; 13 cases had dim partial CD200 and 4 had uniform CD200 expression. Twelve of 
17 CD23+/CD200+ MCL were assessed for SOX11 and all were negative. These cases were 
further tested for LEF1 expression by immunohistochemistry and all were negative. The Ki-67 
proliferation rate in CD23+ MCL was highly variable, ranging from 5% to 95%, with 26 of 60 
(43%) cases having a proliferation rate >30%.  
 
There was no significant difference in the frequency of morphologic subtypes between CD23+ 
and CD23-negative MCL. CD200 expression was significantly more common in CD23+ MCL 
than in typical CD23-negative MCL (16.5% vs 4.6%, p=0.0005), and in leukemic non-nodal 
cases than other cases within the CD23+ group. In contrast, SOX11 expression was significantly 
less common in CD23+ MCL cases (55% vs 74%, p=0.027, Table I).  
 
3.3 Treatment and Response 
Detailed treatment information was available in 99 patients. Thirty-six (36%) patients were 
treated with aggressive induction therapy, mainly R-Hyper CVAD therapy (rituximab, 
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fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with 
high dose methotrexate and cytarabine). Sixteen (16%) patients were observed without treatment 
at last follow up and 47 patients received other treatment regimens. After induction, 63 patients 
achieved complete remission (CR) and 32 (32%) patients relapsed, progressed or primary 
refractory. Twelve patients also underwent stem cell transplantation.  
The frequency of patients who received aggressive versus less aggressive induction 
chemotherapy regimens and the frequency of CR rate were not significantly different between 
the CD23+ and CD23-negative MCL groups (p>0.05). However, patients with CD23+ MCL had 
lower rates of relapse/progression or refractory disease were than patients with CD23-negative 
MCL (32% vs 44%, p=0.048).  
 
3.4 Prognosis 
With a median follow-up of 37 months (range 1.6 – 124 months), 16 (16%) of 103 patients had 
died at the time of last follow-up. The 5-year overall survival rate was 84% and the progression-
free survival rate was 59%, significantly better than for patients with CD23-negative MCL (64% 
and 39% respectively, p<0.05; Figure 2 A&B). To examine if this survival advantage is related 
to the inclusion of SOX11-negative cases, the OS and PFS were compared between patients with 
CD23+/SOX11+ MCL versus those with CD23+/SOX11-negative MCL and there was no 
significant difference in both OS and PFS (p>0.05; Figure 2 C&D). Survival was also compared 
between patients with leukemic non-nodal disease (LNN) and those with non-LNN MCL. 
Patients with a LNN presentation showed a trend towards better OS (p=0.12, Figure 2 E). There 
was also no significant difference in PFS (p=0.58; Figure 2 F) 
The prognostic impact of age, leukocyte count, morphology, Ki-67, and MIPI score were 
examined in CD23+ MCL patients. Blastoid/pleomorphic morphology, Ki-67 >30%, and high 
MIPI score were associated with a worse OS (p<0.05, Figure 3 A-C). Both blastoid/pleomorphic 
morphology and high MIPI were associated with a poorer PFS in patients with CD23+ MCL (p = 
0.002 and 0.001, respectively; Figure 3 D & F).  Ki-67 was not associated with PFS (p=0.33; 
Figure 3 E). Age and leukocyte count did not predict OS or PFS in patients with CD23+ MCL. 
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As LNN disease has been associated with a better OS and a tendency towards better PFS when 
all cases of MCL were included (Figure 4 A & B, P=0.009 and 0.128 respectively), OS was 
further compared between CD23+ and CD23-negative groups when patients with LNN disease 
were excluded. As shown in Figures 4 C and D,  CD23 expression was not associated with OS, 
but there is still a trend towards better PFS when patients with LNN disease were excluded 
(P=0.216 and 0.066 respectively)  
 
Multivariate Cox regression analysis was performed to identify independent prognostic factors 
for OS and PFS in all MCL patients, including CD23+ MCL as well as typical CD23-negative 
MCL (Table IV). Ki-67 >30% and high MIPI were significantly associated with shorter OS 
(P=0.00). High MIPI was also significantly associated with shorter PFS (p=0.00). CD23 
expression did not predict survival in multivariate analysis 
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4. DISCUSSION 
Historically, CD23 expression was reported to be absent or rare in MCL, but positive in 
CLL/SLL, making this marker useful in distinguishing these two neoplasms (1).  However, using 
the more sensitive technique of flow cytometry immunophenotypic analysis, the frequency of 
CD23+ MCL in several small series studies has varied from 0% to 45% [15-17, 20-22]. In this 
large retrospective study, we assessed for CD23 in 798 cases of MCL and 103 (13%) cases were 
CD23+. In almost all cases, CD23 was expressed dimly and, in about two thirds of cases, CD23 
expression was also partial. Only occasional cases had dim-moderate intensity expression and no 
cases were strongly for CD23+.  
 
In this cohort, patients with CD23+ MCL had a lower median age and lower frequency of 
patients older than 60 years that in CD23-negative MCL patients. Patients with CD23+ MCL 
also more frequently had stage 4 disease with bone marrow involvement as well as an elevated 
leukocyte count. Not surprisingly, a leukemic non-nodal (LNN) presentation was significantly 
more common in patients with CD23+ MCL than those with CD23-negative MCL (42% versus 
11%). This result is in contrast to a study by Kelemen et al[21] who showed a similar frequency 
of bone marrow and peripheral blood involvement, but a higher frequency of extranodal non-
medullary disease in patients with CD23+ MCL compared with patients with CD23-negative 
MCL. 
 
There are no studies in literature correlating CD23 and SOX11 expression in MCL. We found 
that CD23+ MCL is more often SOX11 negative than CD23-negative MCL (p=0.027, Table 1). 
In addition, CD23 expression was significantly associated with CD200 expression, 17% in 
CD23+ MCL group vs 4.6% in CD23-negative MCL. In an earlier, independently performed 
study from our department, Hu and colleagues reported that 76% of cases of CD200+ MCL 
express CD23.[23] With these correlations, we identified a small subgroup of MCL cases with 
CLL-like features, being associated commonly with a leukemic presentation and with an 
immunophenotype similar to CLL/SLL, being CD23+, CD200+, and SOX11-negative. CD23 
expression is often used as a marker to distinguish MCL from CLL/SLL. However, cases of 
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CD23+ MCL with CLL-like features are diagnostically challenging. Although there are well 
established morphological criteria, MCL may show a variety of histologic and cytologic patterns, 
some of which can mimic CLL/SLL. It can be especially difficult to distinguish MCL from 
CLL/SLL in peripheral blood or bone marrow.[30-32]  For some of these MCL cases with CLL-
like features, it can be challenging (if not impossible) to distinguish them from CLL/SLL by 
morphology and flow cytometry, even including SOX11 immunohistochemistry. In such cases, 
immunohistochemistry for cyclin D1 and FISH or karyotype to identify CCND1/IGH or 
t(11;14)(q13;q32) are the diagnostic tests. To avoid misdiagnosing these cases as CLL/SLL, an 
immunohistochemical study for cyclin D1 should be performed on new cases of CLL/SLL. 
 
There are limited data available in the literature regarding the prognostic significance of CD23 
expression in MCL. Kelemen et al [21] studied 14 patients of CD23+ MCL and compared this 
group to 33 patients with CD23-negative MCL and found that CD23 expression was associated 
with improved event-free survival (p=0.02) and possibly OS (p=0.07). However, CD23 was not 
an independent prognostic factor by multivariate analysis. In a study of 372 patients with CD5+ 
B cell lymphoproliferative disorders evaluated by flow cytometry immunophenotyping, 
DiRaimondo et al[33] reported that CD23 expression was associated with improved survival; 
MCL cases were not separately analyzed in this study. Gong et al [16] did not detect a survival 
difference according to CD23 expression, although the number of cases in their report was small 
and follow-up was short.  In this study, we compared 103 cases of CD23+ MCL to a group of 
240 patients with typical CD23-negative MCL, by far the largest series of CD23+ MCL. We 
found that the median OS and PFS were significantly better in patients with CD23+ MCL than in 
patients with CD23-negative MCL (p<0.05 for both) by univariate analysis. However, prognostic 
significance was lost partially when LNN cases were excluded; suggesting that the prognostic 
effect is at least partially related to the more frequent LNN form in the CD23+ group. 
Importantly, this survival advantage does not appear to be entirely related to the inclusion of 
SOX11-negative cases because the survival of patients with CD23+/SOX11-negative MCL was 
similar to those with CD23+/SOX11+ MCL. CD23 expression was not an independent 
prognostic factor in multivariate analysis.  
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In summary, in this study of a large cohort of MCL cases we observed CD23 expression in 13%. 
CD23 expression is usually dim and partial in MCL, unlike the moderate to strong positivity 
often seen in CLL/SLL. CD23 expression in MCL correlates with a higher frequency of CD200 
expression, lower frequency of SOX11 expression, and a higher frequency of leukemic non-
nodal presentation. Since previous studies of CD23+ MCL in the literature had a limited number 
of patients, little data are available regarding prognostic factors in CD23+ MCL patients to date. 
Here we assessed prognostic factors and show that morphology and MIPI score predicted for OS 
and PFS and that Ki-67 >30% was associated with a worse overall survival. CD23 expression 
also predicts a better OS and PFS in MCL patients by univariate analysis, although the 
evaluation is somewhat limted by the various treatments. Lastly, this is the first study in the 
literature that identified a small subgroup of MCL cases that were CD23+, CD200+, SOX11-
negative, and a leukemic presentation, features similar to CLL/SLL. These cases pose a 
diagnostic challenge and stress the importance of assessing for cyclin D1 expression and/or 
CCND1 rearrangement in any newly diagnosed CLL/SLL or other CD5+ small B cell leukemia 
and lymphoma.   
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Figure Legends 
 
Figure 1. A representative case of CD23+ mantle cell lymphoma.  The lymphoma cells grew in a 
diffuse pattern (H&E, 400X) and were CD20+, Cyclin D1+, SOX11+, and CD23+ 
(Immunohistochemistry, 400X).  Flow cytometry study showed a kappa-restricted monoclonal B 
cell population that was positive for CD5, CD19, and CD23 (partial).  
 
Figure 2. CD23 expression was associated with improved overall survival (OS) (A) and 
progression free survival (PFS) (B) in all MCL patients. But within the CD23+ MCL group, 
SOX11 expression or leukemic non-nodal disease are not associated with OS (C & E) and PFS 
(D & F). 
 
Figure 3. Prognostic factors might be associated with overall survival (OS) and progression free 
survival (PFS) in CD23+ MCL: blastoid/pleomorphic type (A & D), Ki-67 using 30% as cutoff 
value (B & E), high MIPI (C & F). 
 
Figure 4. Leukemic non-nodal disease is associated with better overall survival (OS, A) but not 
progression free survival (PFS, B) in all MCL. When these leukemic non-nodal cases are 
excluded, CD23 expression is not associated with OS (C), but has a tendency towards a better 
PFS (D). 
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Table I: Clinical features of patients with CD23+ vs typical CD23-negative MCL 
 
  
CD23+ MCL (n=103) 
%(Positive/Evaluated) 
CD23-Negative MCL (n=240) 
%(Positive/Evaluated) P 
Medium age (yrs, range) 63 (44-88) 67 (29-95) 0.018a 
Age >60 (yrs) 65 (67/103) 76 (182/240) 0.048a 
Male:Female 81/22 199/41 0.364 
BM+ 89 (90/101) 78 (178/228) 0.021a 
Stage IV 87 (90/103) 77 (180/234) 0.027a 
Elevated WBC  33 (29/89) 18 (36/200) 0.009a 
Elevated serum LDH  26 (23/88) 27 (52/193) 1.000 
High MIPI 18 (15/85) 24 (38/160) 0.329 
Leukemic Non-Nodal 
Presentation 42 (43/103) 11 (26/239) 0.0001a 
Blastoid/pleomorphic 19 (20/103) 20 (49/240) 0.884 
CD200+ 17 (17/103)                 4.6 (11/240) 0.001a 
SOX11+ 55 (29/53) 74 (64/87) 0.027a 
 Ki67 >30% 43 (26/60) 43 (65/152) 1.000 
Initial chemo 
  
0.122 
    HCVAD+R 36 (36/99) 43 (95/219) 
     Other 47 (47/99)   46 (100/219) 
     Observation            16 (16/99) 11 (24/219) 
 a: all these parameters are statistically significantly different in the two groups. 
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Table II. Clinical features of patients with CD23+ MCL with or without SOX11 expression 
 
  
CD23+/SOX11+  MCL 
(n=29) 
%(Positive/Evaluated) 
CD23+/SOX11-negative MCL 
(n=24)   
%(Positive/Evaluated) P 
Medium age (yrs, range) 67 (46-88) 65 (44-80) 0.371 
Age >60 (yrs) 79 (23/29) 63 (15/24) 0.227 
Male:Female 21/8 19/5 0.750 
BM+ 86 (25/29) 96 (22/23) 0.368 
Stage IV 86 (25/29) 96 (23/24) 0.362 
Elevated WBC  32 (7/22) 55 (12/22) 0.223 
Elevated serum LDH  27 (6/22) 19 (4/21) 0.721 
High MIPI 35 (7/20) 18 (4/22) 0.298 
Leukemic Non-Nodal 
Presentation 41 (12/29) 54 (13/24) 0.415 
Blastoid/pleomorphic 21 (6/29) 13 (3/24) 0.884 
CD200+ 0 (0/29) 50 (12/24) 0.000a 
Ki67 >30% 42 (8/19) 33 (5/15) 0.728 
Initial chemo 
 
 
 
    HCVAD+R 41 (12/29) 28 (6/22) 
     Other 48 (14/29) 36 (8/22) 
     Observation 11 (3/29) 36 (8/22) 0.039a 
a: all these parameters are statistically significantly different in the two groups. 
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Table III. Clinical features of patients with leukemic non-nodal (LNN) vs Non-LNN  CD23+ MCL 
 
  
CD23+/LNN  MCL 
(n=43) 
%(Positive/Evaluated) 
CD23+/Non-LNN MCL (n=60)   
%(Positive/Evaluated) P 
Medium age (yrs, range) 64 (46-88) 63 (44-83) 0.247 
Age >60 (yrs) 67 (29/43) 63 (38/60) 0.682 
Male:Female 35/8 46/14 0.632 
BM+ 100 (43/43) 81 (47/58) 0.002a 
Stage IV 100 (43/43) 82 (49/60) 0.002a 
Elevated WBC  74 (28/38) 14 (7/51) 0.000a 
Elevated serum LDH  24 (9/37) 27 (14/51) 0.809 
High MIPI 31 (11/36) 8 (4/50) 0.009a 
Blastoid/pleomorphic 5 (2/43) 13 (3/24) 0.341 
CD200+ 33 (14/43) 5 (3/60) 0.000a 
Ki67 >30% 25 (4/16) 59 (26/44) 0.039a 
Initial chemo 
 
 
 
    HCVAD+R 29 (12/42) 40 (23/57) 
 
    Other 45 (19/42) 49 (28/57) 
     Observation 26 (11/42) 11 (6/57) 0.288 
    
a: all these parameters are statistically significantly different in the two groups. 
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Table IV. Multivariate analysis in all MCL cases  
       Overall survival   Progression free survival  
  HR 95%CI P   HR 95%CI P 
CD23+ 0.98 0.35-2.75 0.96 
 0.84 0.40-1.77 0.65 
Ki67>30% 5.82 2.22-15.27 0.00a 
 1.79 0.86-3.70 0.12 
MIPI High 3.69 1.70-8.05 0.00a 
 2.7 1.43-5.07 0.00a 
Blastoid/Pleumorphic 0.76 0.32-1.82 0.53 
 1.44 0.67-3.07 0.35 
Leukemic Non-Nodal 
Presentation 0.40 0.08-2.11 0.28   0.73 0.25-2.10 0.56 
a: These parameters are statistically significantly different in the two groups. 
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CD23+ Mantle cell lymphoma (MCL) Highlights: 
 CD23 expression in MCL is dim/partial, in contrast to moderate/strong in CLL/SLL;  
 CD23 expression is associated with better prognosis in patients with MCL; 
 CD23 expression in MCL correlates with: 
o A higher frequency of CD200 expression 
o A lower frequency of SOX11 expression 
o A higher frequency of leukemic non-nodal presentation 
 A small subset of CD23+ MCL has features similar to CLL (CD200+, SOX11-, leukemic) 
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